Table 1.

Definitions and source of contributing data for the main study outcome.

Lp-PLA2 assessment tool	Val279Phe, loss-of-function variant common in East Asians	Four loss-of-function variantsa, rare in Europeans and South Asians		Val379Ala, modest impact variant				Darapladib
Data sources	Systematic review: up to 12 East Asian studies	De-novo genotyping and participant-level data: up to eight European or South Asian ancestry studies from the CHD Exome+ consortium19-26 De-novo genotyping and study-level data: up to 15 European ancestry studies from the MICAD Exome consortium38 and three European ancestry studies from the CHARGE Consortium17,29 Plus publicly available consortium data						Systematic review: up to five randomized clinical trials6,7,39-41 from a systematic review
Endpoint	Number of studies and unique individuals contributing to analyses; n total or cases/controls
Coronary heart disease b	Seven East Asian studiesc	Eight European or South Asian ancestry studies from the CHD Exome+ consortium19-26 d	15 European ancestry studies from the MICAD Exome consortium38 c	Eight European or South Asian ancestry studies from the CHD Exome+ consortium19-26 d	Eight European ancestry studies from the MICAD Exome consortium38 c	14 European ancestry studies from the CARDIoGRAM consortium27 e	Four European or South Asian ancestry studies from the C4D consortium28 e	Two phase 3 randomized clinical trials of darapladib6,7 c
	10,088 cases 15,199 controls	35,829 cases 44,948 controls	35,533 cases 64,130 controls	32,196 cases 41,464 controls	14,976 cases 32,084 controls	20,315 cases 58,419 controls	15,420 cases 15,062 controls	3364 cases 25,490 non-cases
Lp-PLA2 activity f	12 East Asian studiesc	One European ancestry study from the CHD Exome+ consortium25 d	One European ancestry study from the CHARGE consortium29 c	Two European ancestry studies from the CHD Exome+ consortium22,23,25 d		Three European ancestry studies from the CHARGE consortium17 c		Three phase 2 randomized clinical trials39-41 c
	8468	1240	8564	2173		11,662		854